Poly(I)-Poly(C12U) |
|
|
Brand Name: Ampligen ![Audio](https://webarchive.library.unt.edu/eot2008/20090130214237im_/http://aidsinfo.nih.gov/ImageFiles/spIco.jpg) |
Drug Class: Opportunistic Infection and Other Drugs
|
Poly(I)-poly(C12U), also known as Ampligen, is a type of antiviral drug called a biological response modifier. These types of drugs appear to restart human immune defenses against viruses and tumors.
|
|
|
|
HIV/AIDS-Related Uses![](https://webarchive.library.unt.edu/eot2008/20090130214237im_/http://aidsinfo.nih.gov/ImageFiles/blue_dot.gif)
|
|
|
|
Poly(I)-poly(C12U) is an investigational medicine and is not yet approved by the FDA for use outside of clinical trials. It is being studied to see how well it works alone or in combination with other anti-HIV medicines during interruption of standard anti-HIV treatment. Poly(I)-poly(C12U) does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
|
|
|
|
In addition to being studied for its use against HIV, poly(I)-poly(C12U) is being studied to see how well it works against hepatitis viruses, chronic fatigue syndrome, and some cancers.
|
|
|
|
Dosage Form/Administration![](https://webarchive.library.unt.edu/eot2008/20090130214237im_/http://aidsinfo.nih.gov/ImageFiles/blue_dot.gif)
|
|
|
|
Poly(I)-poly(C12U) comes in liquid form that is given by injection into a vein.
|
|
|
|
Recommended Daily Dose![](https://webarchive.library.unt.edu/eot2008/20090130214237im_/http://aidsinfo.nih.gov/ImageFiles/blue_dot.gif)
|
|
|
|
Clinical trials have studied poly(I)-poly(C12U) 400 mg given twice weekly.
|
|
|
|
Contraindications![](https://webarchive.library.unt.edu/eot2008/20090130214237im_/http://aidsinfo.nih.gov/ImageFiles/blue_dot.gif)
|
|
|
|
Because poly(I)-poly(C12U) is still in early clinical trials, little information is available on its safety in different individuals. Individuals should tell their doctor about any medical problems before taking this medicine.
|
|
|
|
Possible Side Effects![](https://webarchive.library.unt.edu/eot2008/20090130214237im_/http://aidsinfo.nih.gov/ImageFiles/blue_dot.gif)
|
|
|
|
In early studies, poly(I)-poly(C12U) has been generally well tolerated, and no serious side effects have been reported. More safety information will be available after further studies.
|
|
|
|
Drug and Food Interactions![](https://webarchive.library.unt.edu/eot2008/20090130214237im_/http://aidsinfo.nih.gov/ImageFiles/blue_dot.gif)
|
|
|
|
A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.
|
Clinical Trials![](https://webarchive.library.unt.edu/eot2008/20090130214237im_/http://aidsinfo.nih.gov/ImageFiles/blue_dot.gif)
|
Click here to search ClinicalTrials.gov for trials that use Poly(I)-Poly(C12U).
|
Manufacturer Information![](https://webarchive.library.unt.edu/eot2008/20090130214237im_/http://aidsinfo.nih.gov/ImageFiles/blue_dot.gif)
|
Poly(I)-Poly(C12U) Hemispherx Biopharma, Inc One Penn Ctr 1617 JFK Blvd, 6th Floor Philadelphia, PA 19103 (215) 988-0080
Ampligen Hemispherx Biopharma, Inc One Penn Ctr 1617 JFK Blvd, 6th Floor Philadelphia, PA 19103 (215) 988-0080
|
Updated January 8, 2009
|